Inventiva Pharma’s impressive €348 million fundraise was featured in Le Monde. The Sofinnova Partners portfolio company (since 2018) successfully raised one of the largest fundraisings in the industry – 90% of which came from American investors specializing in life sciences. This achievement highlights the strength of Inventiva's innovative drug development pipeline and the confidence placed in the company by both European and American investors. Inventiva is one of the rare French biotechs to be listed on the stock exchange in both Europe and the United States. The Dijon-based company is developing a treatment for liver disease. Learn more: https://lnkd.in/eBQxG-EB Kinam Hong, M.D., MBA, CFA Zeliha Chaffin
Sofinnova Partners
Services financiers
Paris, Ile-de-France 28 082 abonnés
Sofinnova Partners is a leading European VC firm in life sciences, specializing in healthcare and sustainability.
À propos
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.8 billion under management. For more information, please visit: www.sofinnovapartners.com
- Site web
-
http://sofinnovapartners.com/
Lien externe pour Sofinnova Partners
- Secteur
- Services financiers
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Paris, Ile-de-France
- Type
- Partenariat
- Fondée en
- 1972
- Domaines
- Pharmaceutical / biotech, Medical devices, Industrial Biotechnology, Sustainability, Biopharma, Medtech, Venture Capital, Private Equity, Biotech et Biotechnology
Lieux
-
Principal
7-11, Boulevard Haussmann
75009 Paris, Ile-de-France, FR
-
1 Pancras Square
N1C 4AG King's Cross, London, GB
-
Via Borgogna, 5
20122 Milan, Lombardy, IT
Employés chez Sofinnova Partners
Nouvelles
-
#ICYMI Bioptimus, a portfolio company of Sofinnova Partners Digital Medicine, was in Roohi M. Peter Labiotech.eu’s top 10 European biotech companies expected to make a significant impact in the industry. Keep an eye on their groundbreaking work! Learn more: https://lnkd.in/dx5kkqqM Edward Kliphuis, Simon Turner, Javier Nunez-Vicandi, Aishwarya Parthasarathy #ai #foundationmodels #digitalmedicine
-
BioWorld ’s Shani Alexander spoke with Antoine Papiernik, Sofinnova Partners’ Chairman and Managing Partner, on why this is such a promising time for the #medtech sector. Antoine discussed what it takes to build a successful medtech company, offering recent examples, such as Shockwave Medical, LimFlow SA, Pi-Cardia, HighLife, Moon Surgical and RefleXion Medical. He also highlighted what it takes to attract investor interest, demonstrating that the technology can transform a specific indication and significantly impact patients. Finally, bringing a product to market and achieving a successful exit takes time—Shockwave Medical, for example, took 12 years to become a billion-dollar company. 🔗Learn more: https://lnkd.in/eCpZJ-Ep
Sofinnova’s Papiernik: ‘It’s a good period for med tech’
bioworld.com
-
We’re delighted to have led the $105 million oversubscribed Series B fundraising round for Purespring Therapeutics and to welcome them as a Sofinnova Partners portfolio company. The recently raised capital will enable Purespring to initiate their Phase I/II clinical trial for PS-002 for IgAN, which is a common, chronic kidney disease principally affecting young adults as well as support their pipeline of novel gene therapy treatments. Purespring was founded on the work of Professor Moin Saleem Professor of Pediatric Renal Medicine at the University of Bristol. It is the first company to successfully treat disease models targeting the podocyte, a specialized cell that is implicated in the majority of renal disease. Learn more: https://lnkd.in/eyhhqfWd Maina Bhaman, Ankeet Jethwa,Julian Hanak #SeriesB #genetherapy #kidneydisease
-
This morning Sifted’s Tom Nugent published a piece highlighting the 10 fastest-growing University spinouts in Europe, by headcount. Great to see Sofinnova Partners portfolio companies Moon Surgical and T-Therapeutics Ltd featured. 🔗 Learn more: https://lnkd.in/e5GAPxTG
-
Congratulations to Pi-Cardia, a Sofinnova Partners portfolio company, on its FDA market clearance for ShortCut™ — the world's first dedicated leaflet modification device, enabling valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction. Earlier this year, the company received Breakthrough Device Designation from the FDA on ShortCut™. Learn more: https://lnkd.in/eGUWgXke Antoine Papiernik, Erez Golan, Eyal Kolka #FDA #cardio #TAVR
-
Invest Europe’s Venture Capital Report showcases great examples of European VC success stories, including Shockwave Medical, a Sofinnova Partners company, which was acquired by Johnson & Johnson for $13.1 billion. Delve into the data, including fundraising details, returns to investors and job creation. ➡️ https://lnkd.in/e7ZUdcf3 #VCReport #VentureCapital #VC #VCimpact
💥 Out now 💥 Our new Venture Capital Report shows the step change in European VC fundraising over the last 10 years ⤵️ 👉 €14.2 billion of capital raised in 2023 👉 3.7x increase over 10 years for France and Benelux 👉 3.4x increase in the Nordics 👉 6.3x increase in Southern Europe Get all the data here (members only) ➡️ https://lnkd.in/e7ZUdcf3 #BuildingBetterBusinesses #VCReport #VentureCapital #VC #VCimpact
-
Congratulations to Genespire, a Sofinnova Partners portfolio company, on its oversubscribed Series B fundraising round. The funding will enable the advancement of GENE202 through a Phase I/II clinical trial and also strengthen the company's pipeline of potential treatments. Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly inherited metabolic diseases. Thank you to Julia Berretta for her significant contributions, as former CEO of Genespire, and welcome aboard, Karen AIACH PIGNET. Learn more: https://lnkd.in/eaVPf8Xf Lucia Faccio, Graziano Seghezzi, Paola Pozzi, Tiziana Rossetti, PhD, Fondazione Telethon, Ospedale San Raffaele #GeneTherapy #BiotechInnovation #Pediatric #Methylmalonicacidemia #RareDiseases
-
🌟Navigating the Biotech Landscape: Insights from Antoine Papiernik of Sofinnova Partners🌟 In an exclusive interview with Maddyness’s Aurélie Pasquier, Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, reflects on the unique dynamics of the #biotech sector, where 75% of new drugs originate from innovative startups. For over 50 years, Sofinnova has been a leader in supporting life sciences ventures, managing €2.8 billion and spearheading numerous innovations. Antoine, who has been with Sofinnova since 1997, highlights the unique challenges faced by the life sciences sector, which are different from those of typical tech startups, even though both rely on venture capital funding. With his strong finance background and a family legacy in medical innovation, Antoine shares key insights on what can drive growth in this specialized field. 🔗 Delve into the full interview: https://lnkd.in/eaMThWRZ #Biotech #LifeSciences #VentureCapital #SofinnovaPartners #Innovation
Biotech : comment Sofinnova résiste à la crise
https://www.maddyness.com
-
Sofinnova Partners a republié ceci
It was fantastic catching up with everyone last night at the welcome reception! Thank you to Antoine Papiernik and Josh Makower for setting the tone with an inspirational Fireside Chat. We're just getting started—see you today for an exciting Day 1. #LSIEurope24
-
+1